Search

By Industry Solutions (2)
By Phase (1)
By Molecule Type (1)
By Therapeutic Area (3)
Covance Events (9)
Geography (3)
Keywords (10)

Filters

Showing results 833 - 848 of 91813 for .

Showing results 833 - 848 of 91813 for .

College of American Pathologists (CAP) - Singapore
The College of American Pathologists certifies that the laboratory named below:Covance Central Lab Svcs Inc - Covance Asia Pte Ltd - Singapore, Singapore - Tuf ail Syed, MD has met all applicable standards for accreditation and is hereby accredited by the College of American Pathologists' Laboratory Accreditation Program. Reinspection should occur prior to March 15, 2016 to maintain accreditation.
CAP - Indianapolis, U.S.
CAP - Indianapolis, U.S. accreditation certificate
CLIA - Indianapolis, U.S.
CENTERS FOR MEDICARE & MEDICAID SERVICES CLINICAL LABORATORY IMPROVEMENT AMENDMENTS - CERTIFICATE OF ACCREDITATION
CLIA Verification of Director Change Letter
This letter is to confirm receipt of correspondence and/or information dated December 27, 2011 regarding the following change(s) within your laboratory: Current Director: William E. Tarr, Jr., M.D.
Clinical Laboratory Improvement Amendments (CLIA) - Fort Myers
CENTERS FOR MEDICARE & MEDICAID SERVICES CLINICAL LABORATORY IMPROVEMENT AMENDMENTS - CERTIFICATE OF REGISTRATION
GDPMS - Singapore
HSA TS-01:R2.1 Good Distribution Practice for Medical Devices - Singapore
Ministry of Health - Singapore
APPROVAL FOR SPECIALISED TESTS AND SERVICES UNDER FIFTH SCHEDULE OF THE PRIVATE HOSPITALS AND MEDICAL CLINICS (PHMC) REGULATIONS
NGSP - Kawagoe, Japan
CERTIFICATE OF TRACEABILITY - This certifies that CB Laboratory, using Bio-Rad Variant II Turbo has participated in and successfully completed NGSP Level I Laboratory certification and is traceable to the Diabetes Control and Complications Trial Reference method. The comparison was performed with: University of Missouri SRL#9
NGSP - Geneva, Switzerland
CERTIFICATE OF TRACEABILITY - Variant II Turbo has participated in and successfully completed NGSP Level I Laboratory certification and is traceable to the Diabetes Control and Complications Trial Reference method. The comparison was performed with: University of Missouri SRL#9
Full page photo
CERTIFICATE OF TRACEABILITY - This certifies that Covance, using Bio-Rad Variant II Turbo has participated in and successfully completed NGSP Level I Laboratory certification and is traceable to the Diabetes Control and Complications Trial Reference method. The comparison was performed with: University of Missouri SRL#9
NGSP - Shanghai, China
Certificate of Traceability - This certifies that Covance Shanghai, using Bio-Rad Variant II has participated in and successfully completed NGSP Level I Laboratory certification and is traceable to the Diabetes Control and Complications Trial Reference method. The comparison was performed with: University of Missouri SRL#9
NGSP - Singapore
Certificate of Traceability - This certifies that Covance Asia Pte Ltd, using Bio-Rad Variant II has participated in and successfully completed NGSP Level I Laboratory certification and is traceable to the Diabetes Control and Complications Trial Reference method. The comparison was performed with: University of Missouri SRL#9
INNOVATIVE SOLUTIONS TO ADVANCE IMMUNE-MEDIATED INFLAMMATORY DISEASE DRUG DEVELOPMENT
Recent scientific advances have propelled our understanding of the immune system's regulation, as well as identified targets that play key roles in inflammatory and autoimmune diseases. Immune-Mediated Inflammatory Diseases (IMIDs) share common pathways, creating the opportunity to treat multiple inflammatory diseases and improve treatment for millions of people worldwide.
Evaluating New Antiviral Drugs and Antibiotic Drug Candidates: A Journey from Discovery to Post-Marketing
Infectious disease drug and vaccine development has witnessed many unique advances, most notably in the fights against hepatitis C virus and HIV. Now, improved microbial identification and quantitative technological platforms offer drug developers new tools for many precise and relatively low-cost methods to develop assays and interpret results.
Addressing Challenges In Immune-Mediated Inflammatory Disorder Clinical Trials
Addressing Challenges In Immune-Mediated Inflammatory Disorder Clinical Trials
Rare Disease and Orphan Drug Solutions
Learn how to address key development challenges, including patient access, unique study design and the need for cross-functional global expertise.